Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Non-Hodgkin 6Lymphoma, Large-Cell, Immunoblastic 6Hodgkin Disease 6Burkitt Lymphoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Sezary Syndrome 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Prostatic Neoplasms 4Multiple Myeloma 4Melanoma 4Lung Neoplasms 4Leukemia 4Immunoblastic Lymphadenopathy 4Carcinoma, Non-Small-Cell Lung 4Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Blast Crisis 3

Interventions

Docetaxel 3Carboplatin 3motexafin gadolinium 2figitumumab 2cemiplimab 2alpha-2'-deoxythioguanosine 2Paclitaxel 2vandetanib 1temoporfin 1tanespimycin 1brigatinib 1Vinorelbine 1Temozolomide 1Radiotherapy 1Radiosurgery 1Pemetrexed 1Oxaliplatin 1Gemcitabine 1Everolimus 1Erlotinib Hydrochloride 1Crizotinib 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Large Cell × tanespimycin × Clear all
NCT01362400 2014-05-19

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
226 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡